PMID- 35950052
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220813
IS  - 2504-3889 (Electronic)
IS  - 2504-3889 (Linking)
VI  - 5
IP  - 1
DP  - 2022 Jan-Dec
TI  - Medicinal Cannabis for the Treatment of Chronic Refractory Pain: An Investigation 
      of the Adverse Event Profile and Health-Related Quality of Life Impact of an Oral 
      Formulation.
PG  - 20-31
LID - 10.1159/000521492 [doi]
AB  - INTRODUCTION: Medicinal cannabis is prescribed in Australia for patients with 
      chronic refractory pain conditions. However, measures of safety and effectiveness 
      of different cannabinoids are lacking. We designed an observational study to 
      capture effectiveness, adverse events (AEs), and health-related quality of life 
      (HRQoL) measures in patients prescribed an oral medicinal cannabis formulation at 
      Cannabis Access Clinics through the Cannabis Access Clinics Observational study 
      (CACOS). OBJECTIVES: We aimed to evaluate effectiveness, reported AEs, and change 
      in patient-reported outcomes in individuals prescribed a cannabinoid oil 
      formulation for management of chronic pain. METHODS: A cross-sectional analysis 
      was conducted on patients prescribed an oil formulation of 
      Delta9-tetrahydrocannabinol and cannabidiol for pain symptoms of at least 3-month 
      duration. Clinician-reported AEs were organized by system, organ, class, and 
      frequency. Analysis of patient-reported responses to a questionnaire was 
      conducted using published minimal clinically important differences to determine 
      meaningful change in HRQoL over time. RESULTS: More than half (n = 91/151, 60.3%) 
      of the participants experienced at least one AE during the observation period 
      (mean 133 +/- 116 days). No serious AEs were reported. Patient-reported pain impact 
      scores were significantly reduced across the cohort (p = 0.034), and pain 
      intensity scores verged on significance (p = 0.053). The majority of patients saw 
      meaningful improvements in sleep (49.3%) and fatigue (35.6%). CONCLUSION: This 
      analysis presents real-world data collected as part of standard of care. More 
      than one-third of patients benefited from oral medicinal cannabis, which is 
      impactful given the refractory nature of their pain. Amelioration of the impact 
      of pain confirms continued prescribing of this formulation and validates our 
      observational methodology as a tool to determine the therapeutic potency of 
      medicinal cannabinoids.
CI  - Copyright (c) 2022 by S. Karger AG, Basel.
FAU - Abelev, Sarah
AU  - Abelev S
AD  - Applied Cannabis Research, Sydney, New South Wales, Australia.
FAU - Warne, Leon N
AU  - Warne LN
AD  - Little Green Pharma, Perth, Washington, Australia.
AD  - College of Science, Health, Engineering and Education, Murdoch University, Perth, 
      Washington, Australia.
AD  - School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research 
      Institute, Curtin University, Perth, Washington, Australia.
FAU - Benson, Melissa
AU  - Benson M
AD  - Applied Cannabis Research, Sydney, New South Wales, Australia.
FAU - Hardy, Mark
AU  - Hardy M
AD  - CA Clinics, Sydney, New South Wales, Australia.
FAU - Nayee, Sunny
AU  - Nayee S
AD  - Pain Management Department, Charing Cross Hospital, Imperial College Healthcare 
      Trust, London, United Kingdom.
FAU - Barlow, John
AU  - Barlow J
AD  - Applied Cannabis Research, Sydney, New South Wales, Australia.
LA  - eng
PT  - Journal Article
DEP - 20220209
PL  - Switzerland
TA  - Med Cannabis Cannabinoids
JT  - Medical cannabis and cannabinoids
JID - 101765665
PMC - PMC9235063
OTO - NOTNLM
OT  - Adverse events
OT  - Cannabinoids
OT  - Improved pain impact
OT  - Improved pain intensity
OT  - Medicinal cannabis
COIS- L.N.W. reports personal fees from Little Green Pharma, outside the submitted 
      work. All other authors have no conflicts of interest to declare.
EDAT- 2022/08/12 06:00
MHDA- 2022/08/12 06:01
PMCR- 2022/02/09
CRDT- 2022/08/11 02:24
PHST- 2021/11/22 00:00 [received]
PHST- 2021/12/10 00:00 [accepted]
PHST- 2022/08/11 02:24 [entrez]
PHST- 2022/08/12 06:00 [pubmed]
PHST- 2022/08/12 06:01 [medline]
PHST- 2022/02/09 00:00 [pmc-release]
AID - mca-0005-0020 [pii]
AID - 10.1159/000521492 [doi]
PST - epublish
SO  - Med Cannabis Cannabinoids. 2022 Feb 9;5(1):20-31. doi: 10.1159/000521492. 
      eCollection 2022 Jan-Dec.